The effect of feeding and starvation on the proliferative competence and onset of cell cycle re-entry in all cell cycle-gated cells. by Eudald Pascual-Carreras (12115380)

The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

“…<i>n</i> = 2–4 biological replicates per condition, with 15 individuals per replicate. Significance levels for Student <i>t</i> test are indicated for adjusted <i>p</i> values: *<i>p</i> < 0.05, ***<i>p</i> < 0.001, ***<i>p</i> < 0.0001. d: day(s), n.s.: non-significant. …”

The effect of feeding and starvation on the proliferative competence and cell cycle re-entry dynamics of Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

Effects of busulfan treatment (6 mg/kg) on the epididymis and sperm of mice over a three-week period. by Lingjun Zhao (21763122)

Subjects:

The age-specific incidence rates of NPC and ENKTL across different time-periods. by Shyh-An Yeh (10011348)

Subjects:

Comparison of eye drop instillation success rates across different age groups. by Yuka Kasai (21354922)

Subjects:

Study Data. by Jonathan S. Jahr (2709088)

“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

Study outcomes. by Jonathan S. Jahr (2709088)

“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

Patient characteristics. by Jonathan S. Jahr (2709088)

“…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

Diagnostic value of the 8 hub genes in the GSE52093 dataset. by Wei He (131453)

Subjects:

Expression and diagnostic value of the 8 hub genes in the GSE190635 validation dataset. by Wei He (131453)

Subjects:

Gene set enrichment analysis (GSEA) of the DEGs. by Wei He (131453)

Subjects:

SWFT scores and Lactate Levels. by Burhan Demirkıran (21601740)

Subjects:

HRV Values. by Burhan Demirkıran (21601740)

Subjects:

HRV values (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

Trial Design (Approximately Here). by Burhan Demirkıran (21601740)

Subjects:

Supplementary Figure. by Burhan Demirkıran (21601740)

Subjects:

Mod loss is associated with a reduction of central brain NBs. by Amalia S. Parra (4173004)

Subjects:

Dynamics and functional role of TOR signaling during cell cycle re-entry in Vasa2+/Piwi1+ cells after refeeding. by Eudald Pascual-Carreras (12115380)

Gating strategy of experiment using 30 min EdU pulses experiments in mOr2-Piwi1 juvenile polyps. by Eudald Pascual-Carreras (12115380)